Possible involvement of corticotropin-releasing factor receptor signaling on vascular inflammation

Peptides

Volumn 30, Issue 2, 2009, Pages 365-372

  Inada, Yuri ^a   Ikeda, Keiichi ^a   Tojo, Katsuyoshi ^a   Sakamoto, Masaya ^a   Takada, Yuko ^a   Tajima, Naoko ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CRH receptors; Human aortic endothelial cells; Pitavastatin; TNF ; Urocortin

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; MESSENGER RNA; PITAVASTATIN; TUMOR NECROSIS FACTOR ALPHA; UROCORTIN I; UROCORTIN II; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; DRUG MECHANISM; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; HEART PROTECTION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; VASCULITIS;

AORTA; CELLS, CULTURED; CORTICOTROPIN-RELEASING HORMONE; CYCLIC AMP; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION MEDIATORS; QUINOLINES; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; UROCORTINS;

EID: 58149490802     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2008.10.015     Document Type: Article

References (38)

1. Abe K., Nakayama M., Yoshimura M., Nakamura S., Ito T., Yamamuro M., et al. Increase in the transcriptional activity of the endothelial nitric oxide synthase gene with fluvastatin: a relation with the -786 T > C polymorphism. Pharmacogenet Genomics 15 (2005) 329-336
2. Abuirmeileh A., Harkavyi A., Lever R., Biggs C.S., and Whitton P.S. Urocortin, a CRF-like peptide, restores key indicators of damage in the substantia nigra in a neuroinflammatory model of Parkinson's disease. J Neuroinflamm 4 (2007) 19
3. Arnaud C., Braunersreuther V., and Mach F. Toward immunomodulatory and anti-inflammatory properties of statins. Trends Cardiovasc Med 15 (2005) 202-206
4. Collins T., and Cybulsky M.I. NF-κB: pivotal mediator or innocent bystander in atherogenesis?. J Clin Invest 107 (2001) 255-264
5. García-Villalón A.L., Amezquita Y.M., Monge L., Fernández N., Climent B., Sánchez A., et al. Mechanisms of the protective effects of urocortin on coronary endothelial function during ischemia-reperfusion in rat isolated hearts. Br J Pharmacol 145 (2005) 490-494
6. Gelosa P., Cimino M., Pignieri A., Tremoli E., Guerrini U., and Sironi L. The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation. Vasc Health Risk Manag 3 (2007) 567-577
7. Gulyas J., Rivier C., Perrin M., Koerber S.C., Sutton S., Corrigan A., et al. Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor. Proc Natl Acad Sci U S A 92 (1995) 10575-10579
8. Honjo T., Inoue N., Shiraki R., Kobayashi S., Otsui K., Takahashi M., et al. Endothelial urocortin has potent antioxidative properties and is upregulated by inflammatory cytokines and pitavastatin. J Vasc Res 43 (2006) 131-138
9. Hsu S.Y., and Hsueh A.J. Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med 7 (2001) 605-611
10. Ikeda K., Tojo K., Otsubo C., Udagawa T., Hosoya T., Tajima N., et al. Effects of urocortin II on neonatal rat cardiac myocytes and non-myocytes. Peptides 26 (2005) 2473-2481
11. Ikeda K., Tojo K., Sato S., Ebisawa T., Tokudome G., Hosoya T., et al. Urocortin, a newly identified corticotropin-releasing factor-related mammalian peptide, stimulates atrial natriuretic peptide and brain natriuretic peptide secretions from neonatal rat cardiomyocytes. Biochem Biophys Res Commun 250 (1998) 298-304
12. Ikeda K., Tojo K., Tokudome G., Hosoya T., Tajima N., Oki Y., et al. Urocortin is as an endogenous cardioprotective factor against negative effects of cytokines in the heart. The program of the 83rd Annual Meeting of The Endocrine Society. Denver, CO (2001) 419 [Abstract]
13. Imagawa K., Okayama S., Takaoka M., Kawata H., Naya N., Nakajima T., et al. Inhibitory effect of efonidipine on aldosterone synthesis and secretion in human adrenocarcinoma (H295R) cells. J Cardiovasc Pharmacol 47 (2006) 133-138
14. Karteris E., Hillhouse E.W., and Grammatopoulos D. Urocortin II is expressed in human pregnant myometrial cells and regulates myosin light chain phosphorylation: potential role of the type-2 corticotropin-releasing hormone receptor in the control of myometrial contractility. Endocrinology 145 (2004) 890-900
15. Kavurma M.M., and Bennett M.R. Expression, regulation and function of trail in atherosclerosis. Biochem Pharmacol 75 (2008) 1441-1450
16. Kher N., and Marsh J.D. Pathobiology of atherosclerosis-a brief review. Semin Thromb Hemost 30 (2004) 665-672
17. Kimura Y., Takahashi K., Totsune K., Muramatsu Y., Kaneko C., Darnel A.D., et al. Expression of urocortin and corticotropin-releasing factor receptor subtypes in the human heart. J Clin Endocrinol Metab 87 (2002) 340-346
18. Kitahara M., Kanaki T., Toyoda K., Miyakoshi C., Tanaka S., Tamaki T., et al. NK-104, a newly developed HMG-CoA reductase inhibitor, suppresses neointimal thickening by inhibiting smooth muscle cell growth and fibronectin production in balloon-injured rabbit carotid artery. Jpn J Pharmacol 77 (1998) 117-128
19. Kohno M., Kawahito Y., Tsubouchi Y., Hashiramoto A., Yamada R., Inoue K.I., et al. Urocortin expression in synovium of patients with rheumatoid arthritis and osteoarthritis: relation to inflammatory activity. J Clin Endocrinol Metab 86 (2001) 4344-4352
20. 2γ receptor. Mol Endocrinol 12 (1998) 1077-1085
21. Lam H.C., Kuo S.M., Chuang M.J., Keng H.M., Lin P.R., Liu G.S., et al. Blockade of endothelin-1 release contributes to the anti-angiogenic effect by pro-opiomelanocortin overexpression in endothelial cells. Exp Biol Med (Maywood) 231 (2006) 782-788
22. C(T) method. Methods 25 (2001) 402-408
23. Moffatt J.D., Lever R., and Page C.P. Activation of corticotropin-releasing factor receptor-2 causes bronchorelaxation and inhibits pulmonary inflammation in mice. FASEB J 20 (2006) 1877-1879
24. Moss A.C., Anton P., Savidge T., Newman P., Cheifetz A.S., Gay J., et al. Urocortin II mediates pro-inflammatory effects in human colonocytes via corticotropin-releasing hormone receptor 2α. Gut 56 (2007) 1210-1217
25. Norata G.D., Tibolla G., Seccomandi P.M., Poletti A., and Catapano A.L. Dihydrotestosterone decreases tumor necrosis factor-α and lipopolysaccharide-induced inflammatory response in human endothelial cells. J Clin Endocrinol Metab 91 (2006) 546-554
26. Pisarchik A., and Slominski A. Molecular and functional characterization of novel CRFR1 isoforms from the skin. Eur J Biochem 271 (2004) 2821-2830
27. Preiss D.J., and Sattar N. Vascular cell adhesion molecule-1: a viable therapeutic target for atherosclerosis?. Int J Clin Pract 61 (2007) 697-701
28. Rivier C.L., Grigoriadis D.E., and Rivier J.E. Role of corticotropin-releasing factor receptors type 1 and 2 in modulating the rat adrenocorticotropin response to stressors. Endocrinology 144 (2003) 2396-2403
29. Rivier J., Gulyas J., Kirby D., Low W., Perrin M.H., Kunitake K., et al. Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists. J Med Chem 45 (2002) 4737-4747
30. Saruta M., Takahashi K., Suzuki T., Torii A., Kawakami M., and Sasano H. Urocortin 1 in colonic mucosa in patients with ulcerative colitis. J Clin Endocrinol Metab 89 (2004) 5352-5361
31. Slominski A., Zbytek B., Semak I., Sweatman T., and Wortsman J. CRH stimulates POMC activity and corticosterone production in dermal fibroblasts. J Neuroimmunol 162 (2005) 97-102
32. Takahashi K., Totsune K., Murakami O., Saruta M., Nakabayashi M., Suzuki T., et al. Expression of urocortin III/stresscopin in human heart and kidney. J Clin Endocrinol Metab 89 (2004) 1897-1903
33. Tsatsanis C., Androulidaki A., Dermitzaki E., Charalampopoulos I., Spiess J., Gravanis A., et al. Urocortin 1 and Urocortin 2 induce macrophage apoptosis via CRFR2. FEBS Lett 579 (2005) 4259-4264
34. Tsatsanis C., Androulidaki A., Dermitzaki E., Gravanis A., and Margioris A.N. Corticotropin releasing factor receptor 1 (CRF1) and CRF2 agonists exert an anti-inflammatory effect during the early phase of inflammation suppressing LPS-induced TNF-α release from macrophages via induction of COX-2 and PGE2. J Cell Physiol 210 (2007) 774-783
35. Webster E.L., Lewis D.B., Torpy D.J., Zachman E.K., Rice K.C., and Chrousos G.P. In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation. Endocrinology 137 (1996) 5747-5750
36. Wilbert-Lampen U., Straube F., Trapp A., Deutschmann A., Plasse A., and Steinbeck G. Effects of corticotropin-releasing hormone (CRH) on monocyte function, mediated by CRH-receptor subtype R1 and R2: a potential link between mood disorders and endothelial dysfunction?. J Cardiovasc Pharmacol 47 (2006) 110-116
37. Xiao E., Xia-Zhang L., Vulliemoz N., Rivier J., and Ferin M. Astressin B, a corticotropin-releasing hormone receptor antagonist, accelerates the return to normal luteal function after an inflammatory-like stress challenge in the rhesus monkey. Endocrinology 148 (2007) 841-848
38. Xu J., Hennebold J.D., and Stouffer R.L. Dynamic expression and regulation of the corticotropin-releasing hormone/urocortin-receptor-binding protein system in the primate ovary during the menstrual cycle. J Clin Endocrinol Metab 91 (2006) 1544-1553